Invitrogen™ Human SPG11 Synthetic Peptide

Catalog No.	Quantity
PEP0799	50 μg

Catalog No. PEP0799 Supplier Invitrogen™ Supplier No. PEP0799

Description

Synthetic Peptide

SPG11 Synthetic Peptide, PEP-0799, from Invitrogen.

Hereditary spastic paraplegias (HSPs) are genetically and phenotypically heterogeneous disorders. Spastic paraplegia with thinning of the corpus callosum (ARHSP-TCC) is a relatively frequent form of complicated hereditary spastic paraplegia (cHSP) in which mental retardation and muscle stiffness at onset are followed by slowly progressive paraparesis and cognitive deterioration. Mutations of the SPG11 gene encoding the spatacsin protein have been identified as a major cause of HSP-TCC. Spatacsin is a potential transmembrane protein that is phosphorylated upon DNA damage. It is expressed in all structures of the brain, with a high expression in the cerebellum. SPG11 mutations may occur more frequently in familial than sporadic forms of cHSP without TCC. Kjellin syndrome is found to be associated with mutations in not only the SPG15 gene but also SPG11 gene. Recent studies show Parkinsonism may initiate SPG11-linked HSP TCC and that SPG11 may cause juvenile Parkinsonism.

Specifications

• Gene ID (Entrez): 80208
• Species: Human
• Purification Method: purified
• Accession Number: Q96JI7
• Common Name: Human SPG11
• Concentration: 200 μg/mL
• Content And Storage: -20°C
• Description: Synthetic Peptide
• Format: Liquid
• Formulation: PBS with 0.1% BSA and 0.02% sodium azide; pH 7.2
• For Use With (Application): Blocking Assay, Control
• Gene Symbol: SPG11
• Lyophilized: No
• Preservative: 0.02% sodium azide
• Product Type: Peptide
• Quantity: 50 μg
• Regulatory Status: RUO - research use only
• Storage Buffer: PBS